carbamazepine has been researched along with Dizzyness in 30 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in adults with newly diagnosed epilepsy." | 9.30 | Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. ( Ben-Menachem, E; Biton, V; Brock, M; De Backer, M; Gasalla, T; Grebe, HP; Jensen, L; Li, T; Steiniger-Brach, B; Terada, K, 2019) |
| "Oxcarbazepine is not significantly superior to placebo in the treatment of bipolar disorder in youths." | 9.12 | A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. ( Berv, D; D'Souza, J; Emslie, GJ; Findling, RL; Kowatch, RA; Lehman, RB; Linden, D; McCague, K; Wagner, KD; Wamil, A; Wilens, TE, 2006) |
| "Carbamazepine may cause clinical effects such as dizziness and nystagmus." | 8.31 | Assessment of vestibulo-ocular reflex with video head impulse test in epilepsy patients undergoing carbamazepine monotherapy. ( Adiguzel, A; Demir, I, 2023) |
| "We performed an observational study, collecting data between 2017 and 2019 on serum sodium levels and adverse effects retrospectively in people with epilepsy while receiving treatment with either carbamazepine (CBZ) or oxcarbazepine (OXC)." | 8.02 | Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. ( Berghuis, B; de Haan, GJ; Hulst, J; Koeleman, BPC; Lindhout, D; McCormack, M; Sander, JW; Sonsma, A, 2021) |
| " Duration of tinnitus was the most important long-term prognostic factor of the carbamazepine trial, which indicates the importance of its earlier diagnosis." | 7.96 | Typewriter tinnitus: An investigative comparison with middle ear myoclonic tinnitus and its long-term therapeutic response to carbamazepine. ( Ashaikh, HK; Han, JS; Kim, DK; Park, JM; Park, SN; Park, SY; Vidal, JL, 2020) |
| "This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC." | 5.62 | Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021) |
| " Potentially, females need to be prescribed lower dosages in view of their tendency to reach toxic levels at lower dosages." | 5.42 | Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). ( Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015) |
| "Long-term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in adults with newly diagnosed epilepsy." | 5.30 | Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. ( Ben-Menachem, E; Biton, V; Brock, M; De Backer, M; Gasalla, T; Grebe, HP; Jensen, L; Li, T; Steiniger-Brach, B; Terada, K, 2019) |
| " She was injected with butylphthalide sodium chloride to improve nerve nutritional status and carbamazepine was prescribed to deal with prosopalgia and glossopharyngeal neuralgia." | 5.22 | Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review. ( Chen, Q; Gu, L; He, S; Jing, Z; Luo, K, 2022) |
| "Oxcarbazepine is not significantly superior to placebo in the treatment of bipolar disorder in youths." | 5.12 | A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. ( Berv, D; D'Souza, J; Emslie, GJ; Findling, RL; Kowatch, RA; Lehman, RB; Linden, D; McCague, K; Wagner, KD; Wamil, A; Wilens, TE, 2006) |
| "One-hundred eighty patients with partial or idiopathic generalized nonabsence epilepsy, aged 6 to 65 years, requiring initiation of treatment with carbamazepine (CBZ), valproate (VPA), phenytoin (PHT), phenobarbital (PB), or primidone (PRM) were randomly allocated to two groups according to an open, prospective parallel-group design." | 5.09 | A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. ( Bartoli, A; Cian, P; Fattore, C; Gatti, G; Jannuzzi, G; Monaco, F; Perucca, E, 2000) |
| "Carbamazepine may cause clinical effects such as dizziness and nystagmus." | 4.31 | Assessment of vestibulo-ocular reflex with video head impulse test in epilepsy patients undergoing carbamazepine monotherapy. ( Adiguzel, A; Demir, I, 2023) |
| "We performed an observational study, collecting data between 2017 and 2019 on serum sodium levels and adverse effects retrospectively in people with epilepsy while receiving treatment with either carbamazepine (CBZ) or oxcarbazepine (OXC)." | 4.02 | Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. ( Berghuis, B; de Haan, GJ; Hulst, J; Koeleman, BPC; Lindhout, D; McCormack, M; Sander, JW; Sonsma, A, 2021) |
| " Duration of tinnitus was the most important long-term prognostic factor of the carbamazepine trial, which indicates the importance of its earlier diagnosis." | 3.96 | Typewriter tinnitus: An investigative comparison with middle ear myoclonic tinnitus and its long-term therapeutic response to carbamazepine. ( Ashaikh, HK; Han, JS; Kim, DK; Park, JM; Park, SN; Park, SY; Vidal, JL, 2020) |
| "Thirty patients were enrolled: 10 on gabapentin, 10 on lamotrigine and 10 on carbamazepine monotherapy for epilepsy." | 3.73 | Measuring the effects of antiepileptic medications on balance in older people. ( Blum, D; Fife, TD; Fisher, RS, 2006) |
| " Rates of treatment-emergent adverse events were similar between groups for patients in the safety set." | 2.87 | Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. ( Ben-Menachem, E; Elger, C; Keller, B; Kowacs, PA; Löffler, K; Rocha, JF; Soares-da-Silva, P; Trinka, E, 2018) |
| " There were no statistically significant differences in carbamazepine, carbamazepine epoxide, and phenytoin pharmacokinetic parameters when either drug was administered alone or in combination with tiagabine." | 2.69 | Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. ( Boellner, SW; Cao, GX; Cato, A; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1998) |
| "Gabapentin doses >1,800 mg/day were as well tolerated as doses < or =1,800 mg/day and were not associated with more adverse events." | 2.69 | Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999) |
| " The gabapentin dosage was titrated to effective tolerated dose up to 2400 mg/day." | 2.69 | Gabapentin as adjunctive therapy for partial seizures. ( Bruni, J, 1999) |
| " Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups." | 2.68 | Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997) |
| " dosing schedule of the controlled-release (CR) preparation without a detrimental effect on seizure frequency or adverse effects." | 2.67 | A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine. ( Bruni, J; Dhalla, Z; Sutton, J, 1991) |
| " Two patients with mild symptoms were rechallenged with a lower verapamil dosage (120 mg twice a day) and showed similar rises in CBZ concentration and recurrent neurotoxic symptoms." | 2.66 | Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. ( Brodie, MJ; Macphee, GJ; McInnes, GT; Thompson, GG, 1986) |
| "Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials." | 2.49 | Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. ( Fadda, V; Giovannelli, F; Maratea, D; Verrotti, A; Zaccara, G, 2013) |
| "Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases." | 2.44 | [Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007) |
| "This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC." | 1.62 | Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021) |
| "Perampanel (PER) is a new antiepileptic drug (AED) with a novel mechanism of action." | 1.51 | Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. ( Ishikawa, N; Kobayashi, M; Kobayashi, Y; Tani, H; Tateishi, Y, 2019) |
| " Potentially, females need to be prescribed lower dosages in view of their tendency to reach toxic levels at lower dosages." | 1.42 | Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). ( Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015) |
| "A patient with C6D tetraplegia who sustained intoxication because of drug interaction is presented." | 1.33 | Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report. ( Bluvstein, V; Catz, A; Odi, H; Ronen, J; Vander, T, 2005) |
| "05) change in the serum concentrations of either CBZ or its epoxide metabolite when LTG was added either to the group as a whole or to the nine patients who experienced adverse CNS effects." | 1.30 | Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? ( Berry, DJ; Besag, FM; Newbery, JE; Pool, F; Subel, B, 1998) |
| " The drug's absorption rate increased and its peak plasma levels occurred earlier." | 1.27 | Intermittent carbamazepine intoxication possibly related to altered absorption characteristics of the drug. ( Eadie, MJ; Hooper, WD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 6 (20.00) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| He, S | 1 |
| Chen, Q | 1 |
| Jing, Z | 1 |
| Gu, L | 1 |
| Luo, K | 1 |
| Demir, I | 1 |
| Adiguzel, A | 1 |
| Ben-Menachem, E | 2 |
| Grebe, HP | 1 |
| Terada, K | 1 |
| Jensen, L | 1 |
| Li, T | 1 |
| De Backer, M | 1 |
| Steiniger-Brach, B | 1 |
| Gasalla, T | 1 |
| Brock, M | 1 |
| Biton, V | 1 |
| Han, JS | 1 |
| Park, JM | 1 |
| Park, SY | 1 |
| Vidal, JL | 1 |
| Ashaikh, HK | 1 |
| Kim, DK | 1 |
| Park, SN | 1 |
| Berghuis, B | 2 |
| Hulst, J | 1 |
| Sonsma, A | 1 |
| McCormack, M | 1 |
| de Haan, GJ | 1 |
| Sander, JW | 2 |
| Lindhout, D | 1 |
| Koeleman, BPC | 2 |
| Jang, Y | 1 |
| Yoon, S | 1 |
| Kim, TJ | 1 |
| Lee, S | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Androsova, G | 1 |
| Krause, R | 1 |
| Borghei, M | 1 |
| Wassenaar, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Campbell, E | 1 |
| Coppola, A | 1 |
| Francis, B | 1 |
| Wolking, S | 1 |
| Cavalleri, GL | 1 |
| Craig, J | 1 |
| Delanty, N | 1 |
| Kunz, WS | 1 |
| Lerche, H | 1 |
| Marson, AG | 1 |
| Sills, GJ | 1 |
| Striano, P | 1 |
| Zara, F | 1 |
| Sisodiya, SM | 1 |
| Depondt, C | 1 |
| Trinka, E | 1 |
| Kowacs, PA | 1 |
| Elger, C | 1 |
| Keller, B | 1 |
| Löffler, K | 1 |
| Rocha, JF | 1 |
| Soares-da-Silva, P | 1 |
| Ishikawa, N | 1 |
| Tateishi, Y | 1 |
| Tani, H | 1 |
| Kobayashi, Y | 1 |
| Kobayashi, M | 1 |
| Zaccara, G | 1 |
| Giovannelli, F | 1 |
| Maratea, D | 1 |
| Fadda, V | 1 |
| Verrotti, A | 1 |
| Besi, E | 1 |
| Boniface, DR | 1 |
| Cregg, R | 1 |
| Zakrzewska, JM | 1 |
| Banks, MC | 1 |
| Caruso, PA | 1 |
| Lessell, S | 1 |
| Vander, T | 1 |
| Odi, H | 1 |
| Bluvstein, V | 1 |
| Ronen, J | 1 |
| Catz, A | 1 |
| Weisler, RH | 1 |
| Keck, PE | 1 |
| Swann, AC | 1 |
| Cutler, AJ | 1 |
| Ketter, TA | 1 |
| Kalali, AH | 1 |
| Beydoun, A | 2 |
| Shaibani, A | 1 |
| Hopwood, M | 1 |
| Wan, Y | 1 |
| Fife, TD | 1 |
| Blum, D | 1 |
| Fisher, RS | 1 |
| Wagner, KD | 1 |
| Kowatch, RA | 1 |
| Emslie, GJ | 1 |
| Findling, RL | 1 |
| Wilens, TE | 1 |
| McCague, K | 2 |
| D'Souza, J | 2 |
| Wamil, A | 1 |
| Lehman, RB | 1 |
| Berv, D | 1 |
| Linden, D | 1 |
| Thömke, F | 1 |
| Silberstein, S | 1 |
| Saper, J | 1 |
| Berenson, F | 1 |
| Somogyi, M | 1 |
| Fischer, J | 1 |
| Labar, DR | 1 |
| Harden, C | 1 |
| Cantrell, D | 1 |
| Uthman, BM | 1 |
| Sackellares, JC | 1 |
| Abou-Khalil, B | 1 |
| Ramsay, RE | 1 |
| Hayes, A | 1 |
| Greiner, M | 1 |
| Garofalo, E | 1 |
| Pierce, M | 1 |
| Besag, FM | 1 |
| Berry, DJ | 1 |
| Pool, F | 1 |
| Newbery, JE | 1 |
| Subel, B | 1 |
| Gustavson, LE | 1 |
| Cato, A | 1 |
| Boellner, SW | 1 |
| Cao, GX | 1 |
| Qian, JX | 1 |
| Guenther, HJ | 1 |
| Sommerville, KW | 1 |
| McLean, MJ | 1 |
| Morrell, MJ | 1 |
| Willmore, LJ | 1 |
| Privitera, MD | 1 |
| Faught, RE | 1 |
| Holmes, GL | 1 |
| Magnus-Miller, L | 1 |
| Bernstein, P | 1 |
| Rose-Legatt, A | 1 |
| Bruni, J | 2 |
| Jannuzzi, G | 1 |
| Cian, P | 1 |
| Fattore, C | 1 |
| Gatti, G | 1 |
| Bartoli, A | 1 |
| Monaco, F | 1 |
| Perucca, E | 1 |
| Dhalla, Z | 1 |
| Sutton, J | 1 |
| Macphee, GJ | 1 |
| McInnes, GT | 1 |
| Thompson, GG | 1 |
| Brodie, MJ | 1 |
| Eadie, MJ | 1 |
| Hooper, WD | 1 |
| Jaster, PJ | 1 |
| Abbas, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study on Long-term Outcome and Potential Usefulness fo an Intervention Aimed at Reducing Adverse Effects in Patients With Refractory Epilepsy[NCT03939507] | 1,000 participants (Actual) | Interventional | 2006-11-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carbamazepine and Dizzyness
| Article | Year |
|---|---|
Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review.
Topics: Aspirin; Carbamazepine; Deglutition Disorders; Dizziness; Female; Gabapentin; Glossopharyngeal Nerve | 2022 |
Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Topics: Acetamides; Anticonvulsants; Ataxia; Carbamazepine; Dibenzazepines; Diplopia; Dizziness; Dose-Respon | 2013 |
[Frequently occurring forms of dizziness and their treatment].
Topics: Amines; Anticonvulsants; Betahistine; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnosis, Differe | 2007 |
13 trials available for carbamazepine and Dizzyness
| Article | Year |
|---|---|
Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dizziness; Double-Blind Method; | 2019 |
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Topics: Adult; Alanine Transaminase; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dibenzazep | 2018 |
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antimanic Agents; Ataxia; Bipolar Disorder; Carbamazepine; Delayed-Action Prep | 2005 |
Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study.
Topics: Adult; Aged; Analgesics; Anticonvulsants; Carbamazepine; Diabetic Neuropathies; Dizziness; Dose-Resp | 2006 |
A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.
Topics: Adolescent; Age Factors; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Carbamazepine; Child; D | 2006 |
Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Dizziness; Dose-Response Relationship, Drug | 2008 |
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar | 1997 |
Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dizziness; Drug Interactions; Drug Monitoring; Dr | 1998 |
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Asthenia; Carbamazepine; Cycl | 1999 |
Gabapentin as adjunctive therapy for partial seizures.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Dru | 1999 |
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Dizziness; Drug Administration Sched | 2000 |
A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Ataxia; Attitude of Health Personnel; Attitude to Health; | 1991 |
Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.
Topics: Adult; Carbamazepine; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Synergism; Drug | 1986 |
14 other studies available for carbamazepine and Dizzyness
| Article | Year |
|---|---|
Assessment of vestibulo-ocular reflex with video head impulse test in epilepsy patients undergoing carbamazepine monotherapy.
Topics: Carbamazepine; Dizziness; Epilepsy; Head Impulse Test; Humans; Reflex, Vestibulo-Ocular | 2023 |
Typewriter tinnitus: An investigative comparison with middle ear myoclonic tinnitus and its long-term therapeutic response to carbamazepine.
Topics: Adult; Aged; Anticonvulsants; Audiometry, Pure-Tone; Carbamazepine; Dizziness; Ear, Middle; Early Me | 2020 |
Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Dizziness; Epilepsy; Fatigue; Female; Humans; Hyponatremia; M | 2021 |
Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Diplopia; Dizziness; Dru | 2021 |
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam; | 2017 |
Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dizziness; Drug Resistant Epile | 2019 |
Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticonvulsants; Carbamazepine; Cluster Headac | 2015 |
Midbrain-thalamic ocular neuromyotonia.
Topics: Adult; Anticonvulsants; Carbamazepine; Diplopia; Dizziness; Humans; Isaacs Syndrome; Magnetic Resona | 2005 |
Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.
Topics: Adult; Analgesics, Non-Narcotic; Carbamazepine; Dantrolene; Dizziness; Drug Interactions; Drug Thera | 2005 |
Measuring the effects of antiepileptic medications on balance in older people.
Topics: Aged; Amines; Anticonvulsants; Ataxia; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Epilep | 2006 |
Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?
Topics: Anticonvulsants; Carbamazepine; Child; Diplopia; Dizziness; Dose-Response Relationship, Drug; Drug A | 1998 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Intermittent carbamazepine intoxication possibly related to altered absorption characteristics of the drug.
Topics: Absorption; Carbamazepine; Dizziness; Drug Administration Schedule; Humans; Kinetics; Postural Balan | 1987 |
Erythromycin-carbamazepine interaction.
Topics: Adult; Ataxia; Carbamazepine; Dizziness; Drug Interactions; Erythromycin; Female; Humans; Male; Slee | 1986 |